awmsg logo



ledispavir/sofosbuvir (Harvoni®)


Reference No. 3556

Publication date:
27/10/2017


Appraisal information

ledispavir/sofosbuvir (Harvoni®) 90 mg/400 mg film-coated tablet


Company: Gilead Sciences Ltd
BNF category: Infections
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 26/10/2017

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, ledispavir/sofosbuvir (Harvoni®) cannot be endorsed for use within NHS Wales for the treatment of chronic hepatitis C in adolescents aged 12 to < 18 years.
Statement of Advice (SOA)
Download